References
1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA.
Oral sildenafil in the
treatment of erectile dysfunction. Sildenafil Study Group. N
Engl J Med 1998;338:1397-404.
2. Herrmann HC, Chang G, Klugherz BD, Mahoney PD.
Hemodynamic effects of
sildenafil in men with severe coronary artery disease. N Engl J
Med 2000;342:1622-6.
3. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary
Arterial Hypertension (SUPER) Study Group.
Sildenafil citrate
therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
4. Soulaidopoulos S, Terentes-Printzios D, Ioakeimidis N, Tsioufis KP,
Vlachopoulos C.
Long-term effects of
phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a
systematic review and meta-analysis. Eur Heart J Cardiovasc
Pharmacother 2024;10:403-412.
5. Corbic M, Sretenovic J, Zivkovic V, Jakovljevic V, Nikolic Turnic T.
Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular
Diseases: A Brief Review. Iran J Public Health 2023;52:870-9.
6. Abouelmagd ME, Abdelmeseh M, Elrosasy A, et al. Phosphodiesterase-5 inhibitors use
and the risk of alzheimer’s disease: a systematic review and
meta-analysis. Neurol Sci 2024; 45:5261-70.
7. Kumar A, Kim F, Song DK, Choung JJ.
Polypharmacological
Potential of Phosphodiesterase 5 Inhibitors for the Treatment of
Neurocognitive Disorders. Aging Dis 2024;15:2008-14.
8. Roy S, Kloner RA, Salloum FN, Jovin IS.
Cardiac Effects
of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. Cardiovasc
Drugs Ther 2023;37:793-806.
9. Andersson DP, Landucci L, Lagerros YT, et al. Association of
Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men
With Coronary Artery Disease. J Am Coll Cardiol 2021;77:1535-50.
10. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio
FM. Effect of
sildenafil on haemodynamic response to exercise and exercise capacity in
Fontan patients. Eur Heart J 2008;29:1681-7.
11. Carella MC, Forleo C, Stanca A, et al. Heart Failure and
Erectile Dysfunction: a Review of the Current Evidence and Clinical
Implications. Curr Heart Fail Rep 2023;20:530-41.
12. Xanthopoulos A, Wolski K, Wang Q, et al. Postimplant
Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular
Assist Devices. JACC Heart Fail 2022;10:89-100.
13. Galiè N, Barberà JA, Frost AE, et al. AMBITION
Investigators. Initial
Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.N Engl J Med 2015;373:834-44.
14. Grünig E, Jansa P, Fan F, et al. Randomized Trial of
Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary
Arterial Hypertension. J Am Coll Cardiol 2024;83:473-84.
15. Trolle Lagerros Y, Grotta A, Freyland S, Grannas D, Andersson DP.
Risk of Death in
Patients With Coronary Artery Disease Taking Nitrates
and Phosphodiesterase-5 Inhibitors. J Am Coll Cardiol 2024;83:417-26.
16. AlRuwaili R, Al-Kuraishy HM, Alruwaili M, et al. The potential
therapeutic effect of phosphodiesterase 5 inhibitors in the acute
ischemic stroke (AIS). Mol Cell Biochem 2024;479:1267-78.
17. Benza RL, Grünig E, Sandner P, Stasch JP, Simonneau G.
The nitric
oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension:
from PDE5 to soluble guanylate cyclase. Eur Respir Rev 2024;33:230183.
18. Ahmad N, Wang Y, Ali AK, Ashraf M.Long-acting phosphodiesterase-5
inhibitor, tadalafil, induces sustained cardioprotection
against lethal ischemic injury. Am J Physiol Heart Circ Physiol
2009;297:H387-91.
19. Nagiub M, Filippone S, Durrant D, Das A, Kukreja RC.Long-acting PDE5
inhibitor tadalafil prevents early doxorubicin-induced left
ventricle diastolic dysfunction in juvenile mice: potential role of
cytoskeletal proteins. Can J Physiol Pharmacol 2017;95:295-304.
20. Xiao J, Zhang N, Gao Z, et al. Phosphodiesterase 5 and its inhibitors with ischemic heart
disease: a Mendelian randomization analysis and a real-world study. Eur
Heart J Cardiovasc Pharmacother 2024; pvae081. doi:
10.1093/ehjcvp/pvae081.
21. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease.Eur Heart J 2014;35:1917-24.
22. Larsson SC, Butterworth AS, Burgess S.Mendelianrandomization for cardiovascular diseases: principles and
applications. Eur Heart J 2023;44:4913-24.
23. Bermejo J, Yotti R, García-Orta R, et al. Sildenafil for
Improving Outcomes after VAlvular Correction (SIOVAC) investigators.
Sildenafil for
improving outcomes in patients with corrected valvular heart disease and
persistent pulmonary hypertension: a multicenter, double-blind,
randomized clinical trial. Eur Heart J 2018;39:1255-64.
24. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of
sildenafil on invasive haemodynamics and exercise capacity in heart
failure patients with preserved ejection fraction and pulmonary
hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565-73.
25. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L.
Combination therapy
with bosentan and sildenafil in Eisenmenger syndrome: a randomized,
placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124-31.
26. Etminan M, Sodhi M, Mikelberg FS, Maberley D. Risk of Ocular Adverse
Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in
the US. JAMA Ophthalmol 2022;140:480-4.
27. Stridh A, Pontén M, Arver S, Kirsch I, Abé C, Jensen KB. Placebo
Responses Among Men With Erectile Dysfunction Enrolled in
Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and
Meta-analysis. JAMA Netw Open 2020;3:e201423.
28. Peak TC, Richman A, Gur S, Yafi FA, Hellstrom WJ.
The Role ofPDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
Sex Med Rev 2016;4:74-84.
29. Sanati M, Aminyavari S, Mollazadeh H, Bibak B, Mohtashami E, Afshari
AR. How dophosphodiesterase-5 inhibitors affect cancer?
A focus on glioblastoma multiforme. Pharmacol Rep 2022;74:323-39.
30. Sharpe BP, Hayden A, Manousopoulou A, et al. Phosphodiesterase type
5 inhibitors enhance chemotherapy in preclinical models of esophageal
adenocarcinoma by targeting cancer-associated fibroblasts. Cell Rep Med
2022;3:100541.
31. Hu C. Grants supporting research in China. Eur Heart J 2018;39:2342-4.
32. Hu C. Emergency Protective Measures and Strategies of COVID-19: From
Lifestyle to Traditional Chinese Medicine. Clin Complement Med Pharmacol
2023;3:100089.
33. Hu C. Marine natural products and human immunity: novel
biomedical resources for anti-infection of SARS-CoV-2 and related
cardiovascular disease. Nat Prod Bioprospect 2024;14:12.
34. Kloner RA, Burnett AL, Miner M, et al. Princeton IV consensus
guidelines: PDE5 inhibitors and cardiac health. J Sex
Med 2024;21:90-116.
35.
Vestergaard
N, Søgaard P, Torp-Pedersen
C, Aasbjerg
K. Relationship between treatment of erectile dysfunction and future
risk of cardiovascular disease: A nationwide cohort study. Eur J Prev
Cardiol 2017;24(14):1498-1505.
36. Zuccarello E, Acquarone E, Calcagno E, et al. Development of novelphosphodiesterase 5 inhibitors for the
therapy of Alzheimer’s disease. Biochem Pharmacol 2020;176:113818.
37. Zhang L, Seo JH, Li H, Nam G, Yang HO.
The phosphodiesterase 5
inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a
cGMP/cAMP response element binding protein pathway and decreasing
oxidative damage. Br J Pharmacol 2018;175:3347-60.
38. Roustit M, Giai J, Gaget O, et al.
On-Demand Sildenafil as
a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. Ann
Intern Med 2018;169:694-703.
39. Anand A, Srivastava N, Barwad P, Ramakrishnan S, Roy A, Bhargava B.
Dyspnea in Eisenmenger
syndrome and its amelioration by sildenafil: role of J receptors. Int J
Cardiol 2014;174:574-8.
40. Holt A, Blanche P, Jensen AKG, et al.
Adverse Events
Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors
and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease :
A Case-Crossover Study. Ann Intern Med 2022;175:774-82.
41. Pofi R, Giannetta E, Feola T, et al.
Sex-specific effects of
daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized,
double-blind, placebo-controlled trial. Sci Transl Med
2022;14:eabl8503.